Diadema Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.52M Buy
6,000
+4,000
+200% +$4.06M 0.94% 36
2025
Q4
$2.15M Buy
+2,000
New +$1.91M 0.37% 61
2025
Q3
Sell
-14,816
Closed -$11M 147
2025
Q2
$11.5M Sell
14,816
-4,486
-23% -$3.49M 3.52% 7
2025
Q1
$15.9M Buy
+19,302
New +$16.1M 4.16% 7

Other funds holding LLY

Diadema Partners's LLY Position: Q1 2026 in Review

Diadema Partners increased its Eli Lilly (LLY) stake by 200% in Q1 2026, buying an estimated $4.06M and bringing the position to 6,000 shares worth $5.52M. The position accounts for 0.94% of the portfolio, ranked #36.

Diadema Partners first reported a position in LLY in Q1 2025 and has held it in 4 quarters since. The position peaked at $15.9M in Q1 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Diadema Partners held 6,000 shares of Eli Lilly worth $5.52M as of Q1 2026.
  • Diadema Partners bought 4,000 Eli Lilly shares in Q1 2026, an estimated $4.06M.
  • Eli Lilly made up 0.94% of Diadema Partners's portfolio in Q1 2026, its #36 holding.
  • Diadema Partners first reported a position in Eli Lilly in Q1 2025 and has held it in 4 quarters since.
  • Diadema Partners's Eli Lilly position peaked at $15.9M in Q1 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.